Adjusted Indirect Comparison Using Propensity Score Matching of Osimertinib to Platinum-Based Doublet Chemotherapy in Patients with EGFRm T790M NSCLC Who Have Progressed after EGFR-TKI
Crossref DOI link: https://doi.org/10.1007/s40261-017-0611-3
Published Online: 2017-12-15
Published Print: 2018-04
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Mann, Helen http://orcid.org/0000-0001-9426-2332
Andersohn, Frank
Bodnar, Carolyn
Mitsudomi, Tetsuya
Mok, Tony S. K.
Yang, James Chih-Hsin
Hoyle, Christopher
Funding for this research was provided by:
AstraZeneca
License valid from 2017-12-15